Colorectal cancer
In 1953, the term field cancerization entered medical literature to describe a specific area of epithelium that had been preconditioned to develop cancer. Colorectal cancer begins as uncontrolled growth within the colon or rectum cells lining the large intestine. Most cases start as benign tumors known as polyps before becoming invasive over time. Blood in the stool and changes in bowel movements serve as classic warning signs for patients over fifty years old. Approximately half of all people with colorectal cancer report no symptoms at all during early stages. Weight loss and abdominal pain often appear only after the disease has spread to other parts of the body.
Dietary habits represent the largest environmental risk factor driving disease development globally. Alcohol consumption above one drink per day significantly increases individual risk levels according to evidence-based studies. Red meat and processed meats correlate strongly with higher incidence rates across multiple populations. Obesity and lack of physical exercise contribute to approximately ten percent of all cases worldwide. Inflammatory bowel diseases like Crohn's disease increase risk substantially over decades of chronic inflammation. Genetic syndromes such as Lynch syndrome account for less than five percent of total cases but carry high personal risk.
Colonoscopy remains the primary method for obtaining tissue samples from suspicious areas inside the colon. Flexible sigmoidoscopy cannot screen the right side of the colon where forty-two percent of cancers are found. Fecal occult blood testing is typically recommended every two years for average-risk adults between ages fifty and seventy-five. The American Cancer Society now recommends starting screening at age forty-five due to rising case numbers in younger groups. Virtual colonoscopy via CT scan detects large adenomas but involves radiation exposure and cannot remove growths directly. Stool DNA screening tests look for biomarkers associated with precancerous lesions but generate more false positives than standard immunochemical tests.
Surgery offers a potential cure when cancer remains confined within the wall of the colon or rectum. Chemotherapy drugs including fluorouracil and oxaliplatin extend life expectancy for Stage III and Stage IV patients. Radiation therapy reduces local recurrence rates but carries risks of acute dermatological toxicity affecting twenty-seven percent of recipients. Immunotherapy with pembrolizumab shows promise for tumors exhibiting mismatch repair deficiency and microsatellite instability. Palliative care focuses on relieving symptoms like pain and intestinal obstruction rather than attempting to cure advanced disease. A 2022 study published in The New England Journal of Medicine reported twelve patients achieving complete clinical response without surgery using dostarlimab.
More than one million people develop colorectal cancer annually resulting in approximately seven hundred fifteen thousand deaths globally as of 2010. Developed countries account for more than sixty-five percent of all cases found worldwide today. Incidence rates vary ten-fold between highest regions like Australia and lowest areas such as South-Central Asia. Deaths from colon and rectal cancers among Americans under age fifty increased by roughly one point one percent per year since 2005. Black Americans are about twenty percent more likely to get the disease and forty percent more likely to die from it than other groups. In 2026, colorectal cancer became the primary cause of cancer-related mortality among Americans younger than age fifty.
Up Next
Continue Browsing
Common questions
What is colorectal cancer and how does it develop?
Colorectal cancer begins as uncontrolled growth within the colon or rectum cells lining the large intestine. Most cases start as benign tumors known as polyps before becoming invasive over time.
Who is at highest risk for developing colorectal cancer based on age and lifestyle factors?
Most cases occur in patients over fifty years old, though incidence rates have risen in younger groups since 2005. Alcohol consumption above one drink per day significantly increases individual risk levels according to evidence-based studies.
When should average-risk adults begin screening for colorectal cancer symptoms?
The American Cancer Society now recommends starting screening at age forty-five due to rising case numbers in younger groups. Fecal occult blood testing is typically recommended every two years for average-risk adults between ages fifty and seventy-five.
How effective are current treatments like chemotherapy and immunotherapy for advanced stages?
Chemotherapy drugs including fluorouracil and oxaliplatin extend life expectancy for Stage III and Stage IV patients. A 2022 study published in The New England Journal of Medicine reported twelve patients achieving complete clinical response without surgery using dostarlimab.
What percentage of people with colorectal cancer report no symptoms during early stages?
Approximately half of all people with colorectal cancer report no symptoms at all during early stages. Weight loss and abdominal pain often appear only after the disease has spread to other parts of the body.